Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Rhythm Biosciences Secures Key Manufacturing Deal for ColoSTAT
Rhythm Biosciences (ASX:RHY) has secured a multi-year manufacturing agreement with Quansys Biosciences for its ColoSTAT reagent kits, ensuring scalab
Latest Stories
Neurotech International Secures HREC Approval for Pivotal Phase 3 ASD Study of NTI164
Neurotech International (ASX: NTI) has secured Human Research Ethics Committee (HREC) approval to commence its pivotal Phase 3 clinical study for **NTI16
Algorae Pharmaceuticals Advances Commercial Pathway as AI Platform Validation and Distribution Agreements Gather Pace
Algorae Pharmaceuticals (ASX: 1AI) advances AlgoraeOS validation and signs Dr Reddy's distribution, signals near-term oncology revenue and stronger balance sheet.
Osteopore Expands Orthopaedic Business into Hong Kong with MontsMed Distribution Agreement
Osteopore (ASX: OSX) is set to expand its orthopaedic business into Hong Kong after signing a new distribution agreement with local company MontsMed, marking the next step in the company’s planned commercial expansion across the Asia Pacific region.
Zelira Therapeutics Receives US$33m in Funding to Advance HOPE 1 Autism Program
Zelira Therapeutics (ASX: ZLD) has secured US$32.98 million in new funding after its HOPE 1 special purpose vehicle signed definitive agreements with US-based life sciences investor ThirdGate Capital's TGC Biotechnology Fund.
Proteomics International Obtains Canadian Patent for PromarkerEso Blood Test
Proteomics International Laboratories (ASX: PIQ) has secured new intellectual property protection in Canada, after the country’s Patent Office granted a patent for its PromarkerEso blood test for esophageal adenocarcinoma.
NeuroScientific Biopharmaceuticals Reports Strong Results from Stem Cell Study on Fistulising Crohn's Disease
NeuroScientific Biopharmaceuticals (ASX: NSB) has confirmed that 75% of patients in the first cohort of a study into its StemSmart therapy to treat fistulising Crohn’s disease have demonstrated a positive clinical response following treatment.
Biome Australia Surges with 41% YoY Revenue Growth in Q2 FY26
Biome Australia (ASX: BIO) has reported a robust Q2 FY26, with revenue surging 40.9% year-on-year to $6.48 million, significantly exceeding expectations and reinforcing its trajectory towards its 'Vis
AdAlta inks major CAR-T deal for global development outside China
AdAlta (ASX:1AD) has secured exclusive rights to co-develop Shanghai Cell Therapy Group's BZDS1901 CAR-T therapy outside Greater China, a significant move validating its 'East-to-West' strategy and po
Memphasys Secures CE Mark for Felix System, Unlocking European Market
Memphasys (ASX: MEM) has secured CE Mark approval for its Felix System, unlocking immediate commercial opportunities in Europe and activating binding multi-year contracts in Europe and MENA.
Korean partner backs Invion’s INV043 ahead of Australia first-in-human trial
Invion (ASX: IVX) partners with Hanlim on a $2m non-clinical program to advance INV043 for oesophageal cancer toward first-in-human trials, backed by KDDF grant.
Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial
Neurizon Therapeutics (ASX: NUZ) has successfully raised over $44 million AUD through a multi-pronged capital raise, securing funding to advance its lead drug candidate NUZ-001 through the **H